PECULIARITIES OF CELLULAR, HUMORAL LINKS OF IMMUNITY
AND DYNAMICS OF IMMUNOGLOBULINS IN COMMUNITY-
ACQUIRED PNEUMONIA IN ADULTS AND THEIR IMPORTANCE
FOR DIAGNOSTICS AND PROGNOSIS OF THE DISEASE

Vladyslav Bereznyakov, Oleksiy Korzh, Sergiy Krasnokutskiy

The aim of our work was to study the characteristics of the immune status based on the analysis of the cellular, humoral links of immunity and dynamics of immunoglobulins in adults with community-acquired pneumonia (CAP), and their importance in the pathogenesis and prognosis of the disease.

Materials and methods. The study was carried out in the period 2017-2020 on the basis of the therapeutic department of the Municipal non-profit enterprise “City Clinical Multidisciplinary Hospital № 25” of Kharkiv City Council. The study involved 20 adult patients with CAP aged 18 to 80 years (mean age 36.5±10.3). The control group consisted of 20 apparently healthy individuals (mean age 39.5±12.5). The study of the immune status of patients was carried out by determining the phagocytic index, the content of lymphocytes, CD3+, CD4+, CD8+, CD16+, CD20+ and the level of immunoglobulins of classes A, G, M in the dynamics of the disease: on the first and tenth days after hospitalization.

Results. On the first day of hospitalization, there was a significant imbalance in phagocytosis, T- and B-links of immunity. On the tenth day of treatment, the phagocytic index, the number of CD3+, CD4+, CD8+, CD16+ and CD20+ increased. An increase in Ig M, a decrease in Ig A and Ig G were also noted. Thus, standard therapy for patients with CAP leads to an increase in Ig M, a decrease in Ig A and Ig G. For the treatment of patients with CAP, in addition to standard pharmacotherapy, it is necessary to include drugs that stimulate the immune system.

Conclusions. The features of immune disorders in patients with CAP were revealed: pneumonia increases the imbalance in the cellular link of immunity, the level of CD3+ and CD4+ decreases, there is no dynamics of the relative amount of CD20+. There are no significant changes in the humoral link of the immune status. For the treatment of patients with CAP, in addition to standard pharmacotherapy, it is necessary to include drugs that stimulate the immune system.

Keywords: community-acquired pneumonia, pathogenesis, immunity: cellular and humoral, immunoglobulins, cytokines, inflammation, diagnosis

How to cite:
Bereznyakov, V., Korzh, O., Krasnokutskiy, S. (2021). Peculiarities of cellular, humoral links of immunity and dynamics of immunoglobulins in community-acquired pneumonia in adults and their importance for diagnostics and prognosis the disease. "ScienceRise: Medical Science", 4 (43), 13–16. doi: http://doi.org/10.15587/2519-4798.2021.237712
No. 25” of the Kharkiv City Council. The study involved 20 adult patients with CAP aged 18 to 80 years (mean age 36.5±10.3 years). The diagnosis of CAP was established on the basis of epidemiological, clinical, laboratory, radiological data. Patients with such pathologies as tuberculosis, bronchial asthma, hepatitis B, C and D, HIV, blood diseases and oncological diseases were excluded from the examination.

The control group was formed of 20 apparently healthy people (AHP), which is comparable with patients by age (mean age 39.5±12.5 years) and sex.

Patients were examined according to Medical Standards (National Institute of Tuberculosis and Pulmonology named after F. G. Yanovsky).

The study was conducted in accordance with the requirements of the Helsinki Declaration of the World Medical Association, the Council of Europe Convention on Human Rights and Biomedicine, Good Clinical Practice (GCP) and approved by the Bioethics Commission of Kharkiv Medical Academy of Postgraduate Education (Protocol # 4 of 20.04.2017). Patients who participated were included in the study after signing the informed consent.

Verification of CAP pathogens was performed using microscopic and bacteriological methods. Etiological diagnosis of atypical CAP pathogens included enzyme-linked immunosorbent assay (a set of reagents JSC “Vector-Best-Ukraine”) using the method of latex agglutination to detect bacterial antigen and/or antibodies to the pathogen. At hospitalization, all subjects, in accordance with the standards of the International Society of Pulmonologists and the Recommendations of the National Institute of Tuberculosis and Pulmonology named after F. G. Yanovsky (Kyiv, 2019), were prescribed standard antibiotic therapy.

The study of the immune status of patients was performed by determining the phagocytic index, lymphocyte content, CD3 + (T-lymphocytes), CD4 + (T-helpers), CD8 + (T-suppressors), CD16 + (zero cells), CD20 + (B-lymphocytes) in the serum method immunofluorescence with monoclonal antibodies [5] (used BD FACSCalibur cytometer and reagents from BD Biosciences, USA) and the level of immunoglobulins of classes A, G, M by radial immunodiffusion in agar by Mancini G. et al. [6] (after incubation, the diameters of the precipitation rings were measured with a measuring instrument (binocular magnifier, eyepiece micrometer, ruler, magnifier) and the amount of immunoglobulins was determined from the calibration curve. BD Biosciences reagents, USA were also used for this purpose) in the dynamics of the disease: on the first and 10th day after hospitalization.

Statistical processing of the obtained data was performed using the software package Statistica for Windows 8.0 using Student’s t-test. The results were considered reliable at p <0.05 [7].

3. Research results

In the study of cellular immunity in patients with CAP, significant violations of immune status at the beginning of the disease compared with similar indicators of the AHP group. These changes were manifested by suppression of the activity of the T-cell immune system, phagocytosis and disruption of the B-cell link (Table 1).

In the analysis of immunity in patients with CAP, at the beginning of the disease (on the 1st day of hospitalization) found a significant decrease in phagocytic index (39.0±0.9 %, p<0.001), CD3 + (40.6±1.2, p<0.05), CD4 + (22.5±1.5 %, p<0.001) and CD16+ (10.2±0.5 %, p<0.05) in comparison with these indicators of the AHP group.

In the humoral immune system, patients on the 1st day of hospitalization showed a significant increase in Ig M levels, while the content of Ig A did not differ from the data of the AHP group. The Ig G content did not differ from that of AHP.

Therefore, on the 1st day of hospitalization there is a significant imbalance of phagocytosis, T- and B-links of immunity.

On the 10th day of treatment, the phagocytic index, CD4+ increased, however, the amount of CD3+, CD8+, CD16+ and also CD20+ significantly increased. When comparing the rates of patients with CAP with those of the AHP group, it was found that the phagocytic index and CD4+ content remained without dynamics, and the number of lymphocytes, CD3+, CD8+, CD16+ and CD20+ normalized.

Table 1

| Immunological parameters | Almost healthy people (n=20) | Patients suffering from CAP (n=20) |
|--------------------------|-----------------------------|-----------------------------------|
|                          | On the 1st day of hospitalization | On the 10th day of hospitalization |
| Lymphocytes, %           | 34.0±3.7                     | 32.8±1.1                          |
| CD3+ (T-lymphocytes), %  | 55.2±2.1                     | 40.6±1.2*                         |
| CD4+ (T-helpers), %      | 37.9±1.1                     | 22.5±1.5*                         |
| CD8+ (T-suppressors), %  | 22.5±0.8                     | 18.7±0.7*                         |
| CD16+ (zero cells), %    | 13.1±0.7                     | 10.2±0.5*                         |
| CD20+ (B-lymphocytes), % | 20.3±0.8                     | 17.9±0.4*                         |
| Phagocytic index, %      | 57.2±1.3                     | 39.0±0.9*                         |
| Ig G, g/l                | 8.8±0.9                      | 5.0±0.6*                          |
| Ig A, g/l                | 0.9±0.1                      | 0.7±0.1                           |
| Ig M, g/l                | 1.1±0.1                      | 1.4±0.1*                          |

Note: * – compared with the AHP group (p<0.05); ** – compared with the indicators on the 1st day of hospitalization (p<0.05)
Indicators of humoral immunity were much better, but complete normalization was not observed. In patients with CAP, on the 10th day of treatment, an increase in the concentration of Ig M (1.1±0.1 g/l) was observed compared with the AHP group. There was also a tendency to decrease the content of Ig A (0.9±0.1 g/l) and Ig G (6.4±0.6 g/l).

Thus, the obtained data indicate that when using standard therapy for the treatment of CAP in adult patients, only improvements were observed, but most of them did not reach the data of the AHP group.

4. Discussion of research results

Analysis of clinical manifestations of CAP, depending on the severity, revealed more pronounced syndromes of intoxication and general inflammatory changes, clinical and radiological predominance of lung tissue lesions with pleural effusion syndrome, and in the auscultatory picture – moist small-bubble wheezing and crepitus.

The etiological structure of CAP according to the results of microbiological and enzyme-linked immunosorbent assay was as follows: pneumonia in patients with mild and moderate course was caused in most cases by intracellular pathogens, including Mycoplasma pneumoniae (30 %), gram-positive microflora – Streptococcus pneumoniae; in 25 % of patients the pathogen was not identified. The leading pathogens of moderate pneumonia were Streptococcus pneumoniae (40 %) and mixed cultures of bacteria (20 %), with an increase in the proportion of Staphylococcus aureus (25 %), in addition, gram-negative pathogens (15 %) were detected.

Analysis of changes in cellular and humoral components of immunity in CAP was performed taking into account the severity. It was found that in patients with severe and moderate CAP was accompanied by an increase in the relative number of mature T lymphocytes (CD3+) with a decrease in their absolute value, a decrease in the number of T-helper inducers (CD4+) and an increase in cytotoxic (CD8+).

In the study of immunoglobulins in patients with CAP, the following data were obtained: the level of Ig A tended to increase and the level of IgM to decrease, but the indicators did not differ statistically significantly from the level in AHP. IgG levels were significantly (p <0.05) reduced in patients with CAP.

The results of the analysis of the clinical course and etiological characteristics of CAP of the examined patients reflect the general trends of the disease, consistent with the literature [1, 3, 8].

Indicators of the main classes of immunoglobulins in the initial period of CAP were characterized by lower values than in the AHP group, except for IgA. Dysimmunoglobulinemia on the background of the strengthening of immunocomplex mechanisms and functional insufficiency of the phagocytic unit revealed by us suggests the presence of immunocomplex and autoimmune components in the pathogenesis of complicated pneumonia.

Given the most important regulatory role of immunoglobulins [4, 9, 10], we can assume insufficient intercellular activation of specific factors of the cellular immune system (indirectly confirmed by low T- and B-lymphocytes) in patients with severe disease, which leads to increased infectious process. Thus, in patients with severe CAP and a large amount of lung tissue damage, there is an imbalance of cellular and humoral immune systems, as well as immunoglobulins, which determines, in our opinion, the pathogenetic features of the disease.

Insufficiency of cellular and humoral mechanisms of immunity and imbalance of immunoglobulins in patients suffering from CAP, determines the severity of the disease.

Such changes may indicate a significant violation of immunological reactivity in patients with CAP. One of the mechanisms is a decrease in DNA synthesis, which reduces the rate of cell proliferation, inhibits the recognition of foreign antigens (reduced concentration of CD4+), which, in turn, leads to inhibition of growth and differentiation factors necessary for reproduction and maturation of B-lymphocytes, insignificant stimulation of growth and reproduction of cytotoxic and suppressor T-cells, slowing down of activation of macrophage system, decrease in immune tolerance, killer activity of zero cells [4, 11, 12].

Study limitations. The article considers changes in the levels of cellular and humoral immune systems, as well as the dynamics of immunoglobulins in patients with CAP, using standard pharmacotherapy, however, no correlation analysis between these indicators.

Prospects for further research. The next stage of our study will be to study the production of cytokines in patients with CAP, in order to expand current ideas about the pathogenesis of CAP, its diagnosis and prognosis.

5. Conclusions

The peculiarities of immune disorders in patients with community-acquired pneumonia, which determine the severity of the disease and the volume of lung tissue inflammation.

The inflammatory process in the lungs exacerbates the imbalance in the cellular link of immunity, which is manifested in a more pronounced decrease in the number of total mature T-lymphocytes (CD3+) and T-lymphocytes-helpers (CD4+).

A distinctive feature of the cellular immune system in patients with community-acquired pneumonia is the lack of dynamics of the relative number of B-lymphocytes (CD20+).

In the humoral link of the general immune status of the body of patients with community-acquired pneumonia, significant (p<0.05) changes do not occur.

The tendency to decrease immunoglobulins (Ig G and Ig M) causes severe and moderate course of community-acquired pneumonia and lung damage.

For the treatment of patients with community-acquired pneumonia, in addition to standard pharmacotherapy, it is necessary to include drugs that stimulate immunity.

The findings suggest the importance of studying the immune status of patients with community-acquired pneumonia, which will help develop new approaches to predicting the course of pneumonia, ways to correct metabolic disorders that develop in this condition, and will help identify risk groups for this pathology.

Conflict of interests

The authors declare that they have no conflict of interests.

Financing

The work is a fragment of the research “Mucoactive and herbal medicines for the treatment of cough in acute infectious and inflammatory diseases of the lower respiratory tract” (No. state registration 0117U000595).
References

1. Eshwara, V., Mukhopadhyay, C., Rello, J. (2020). Community-acquired bacterial pneumonia in adults: An update. Indian Journal of Medical Research, 151 (4), 287–302. doi: http://doi.org/10.4103/ijmr.ijmr_1678_19

2. Lanks, C. W., Musani, A. I., Hsia, D. W. (2019). Community-acquired Pneumonia and Hospital-acquired Pneumonia. Medical Clinics of North America, 103 (3), 487–501. doi: http://doi.org/10.1016/j.mcna.2018.12.008

3. Huang, Y., Liu, A., Liang, L., Jiang, J., Luo, H., Deng, W. et. al. (2018). Diagnostic value of blood parameters for community-acquired pneumonia. International Immunopharmacology, 64, 10–15. doi: http://doi.org/10.1016/j.intimp.2018.08.022

4. Brands, X., Haak, B. W., Klarenbeek, A. M., Otto, N. A., Faber, D. R., Lutter, R. et. al. (2020). Concurrent Immune Suppression and Hyperinflammation in Patients With Community-Acquired Pneumonia. Frontiers in Immunology, 11. doi: http://doi.org/10.3389/fimmu.2020.00796

5. Ketlinskiy, S. A. (1999). Sovremennye aspekty izucheniya tsitokinov. Russian Journal of Immunology, 4 (1), 36–52.

6. Mancini, G., Carbonara, A. O., Heremans, J. F. (1965). Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry, 2 (3), 235–239. doi: http://doi.org/10.1016/0019-2791(65)90004-2

7. Lapach, S. N., Chubenko, A. B., Babych, P. N. (2001). Statystycheskye metodы v medyko-bioholohycheskyh yssledovanjah s yspolzovanyem Exel. Kyiv: Moryon, 408.

8. Yu, Y., Fei, A. (2016). Atypical pathogen infection in community-acquired pneumonia. BioScience Trends, 10 (1), 7–13. doi: http://doi.org/10.5582/bst.2016.01021

9. Kolek, V., Jakubeck, P., Losse, S. (2017). Diagnostics and treatment of community-acquired pneumonia – simplicity is the key to success. Vnitrni Lekarstvi, 63 (11), 770–775. doi: http://doi.org/10.136290/vnl.2017.148

10. Johnson, E. E., Wessling-Resnick, M. (2012). Iron metabolism and the innate immune response to infection. Microbes and Infection, 14 (3), 207–216. doi: http://doi.org/10.1016/j.micinf.2011.10.001

11. Nair, G. B., Niederman, M. S. (2021). Updates on community acquired pneumonia management in the ICU. Pharmacology & Therapeutics, 217, 107663. doi: http://doi.org/10.1016/j.pharmthera.2020.107663

12. Cherayil, B. J. (2010). Iron and In immunity: Immunological Consequences of Iron Deficiency and Overload. Archivum Immunologiae et Therapiae Experimentalis, 58 (6), 407–415. doi: http://doi.org/10.1007/s00005-010-0095-9

Received date 16.06.2021
Accepted date 16.07.2021
Published date 30.07.2021

Vladyslav Berezyukov*, PhD, Associate Professor, Department of General Practice – Family Medicine, Kharkiv Medical Academy of Postgraduate Education, Amosova str., 58, Kharkiv, Ukraine, 61176

Oleksiy Korzh. Doctor of Medical Sciences, Professor, Head of Department, Department of General Practice – Family Medicine, Kharkiv Medical Academy of Postgraduate Education, Amosova str., 58, Kharkiv, Ukraine, 61176

Sergiy Krasnokutskiy. PhD, Associate Professor, Department of General Practice – Family Medicine, Kharkiv Medical Academy of Postgraduate Education, Amosova str., 58, Kharkiv, Ukraine, 61176

*Corresponding author: Vladyslav Berezyukov, e-mail: nortaril@gmail.com